1310349-83-7

Basic information

• Product Name: (R)-3-(5-bromo-2-fluoro-phenyl)-2,2-difluoro-3-((R)-2-methyl-propane-2-sulfinylamino)-butyric acid ethyl ester
• Synonyms: (R)-3-(5-bromo-2-fluoro-phenyl)-2,2-difluoro-3-((R)-2-methyl-propane-2-sulfinylamino)-butyric acid ethyl ester
• CAS NO: 1310349-83-7
• Molecular Weight: 444.313
• Mol File: 1310349-83-7.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: (R)-3-(5-bromo-2-fluoro-phenyl)-2,2-difluoro-3-((R)-2-methyl-propane-2-sulfinylamino)-butyric acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-(5-bromo-2-fluoro-phenyl)-2,2-difluoro-3-((R)-2-methyl-propane-2-sulfinylamino)-butyric acid ethyl ester(1310349-83-7)
• EPA Substance Registry System: (R)-3-(5-bromo-2-fluoro-phenyl)-2,2-difluoro-3-((R)-2-methyl-propane-2-sulfinylamino)-butyric acid ethyl ester(1310349-83-7)

Safety Data

• Hazardous Substances Data: 1310349-83-7(Hazardous Substances Data)

Upstream product

• 667-27-6 Ethyl bromodifluoroacetate 
• 198477-89-3 1-(5-bromo-2-fluorophenyl)ethan-1-one 

Downstream Products

• 1310350-06-1 (R)-2-methyl-propane-2-sulfinic acid [(R)-1-(5-bromo-2-fluoro-phenyl)-2,2-difluoro-3-hydroxy-1,3-dimethyl-butyl]-amide 
• 1346145-77-4 (R)-2-(3-amino-3-(5-bromo-2-fluorophenyl)-2,2-difluorobutoxy)acetonitrile 
• 1346145-84-3 (R)-5-(5-bromo-2-fluorophenyl)-6,6-difluoro-5-methyl-2,5,6,7-tetrahydro-1,4-oxazepin-3-amine 
• 1346145-86-5 (R)-N-(bis(4-methoxyphenyl)(phenyl)methyl)-5-(5-bromo-2-fluorophenyl)-6,6-difluoro-5-methyl-2,5,6,7-tetrahydro-1,4-oxazepin-3-amine 
• 1414876-59-7 (R)-5,5-Difluoro-4-{2-fluoro-5-[1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-phenyl}-4-methyl-5,6-dihydro-4H-[1,3]oxazin-2-ylamine 
• 1310350-26-5 (R)-4-(5-bromo-2-fluorophenyl)-5,5-difluoro-4-methyl-5,6-dihydro-4H-1,3-oxazin-2-amine 
• 1310350-11-8 (R)-3-amino-3-(5-bromo-2-fluoro-phenyl)-2,2-difluoro-butan-1-ol 
• 1346146-05-1 (R)-ethyl 2-(4-amino-4-(5-bromo-2-fluorophenyl)-3,3-difluoro-2-methylpentan-2-yloxy)acetate 
• 1346146-30-2 (R)-ethyl 2-(4-(5-bromo-2-fluorophenyl)-4-(1,1-dimethylethylsulfonamido)-3,3-difluoro-2-methylpentan-2-yloxy)acetate 
• 1346146-28-8 (R)-2-(4-(5-bromo-2-fluorophenyl)-4-(1,1-dimethylethylsulfonamido)-3,3-difluoro-2-methylpentan-2-yloxy)acetic acid 
• 1346146-26-6 (R)-N-((R)-4-(allyloxy)-2-(5-bromo-2-fluorophenyl)-3,3-difluoro-4-methylpentan-2-yl)-2-methylpropane-2-sulfinamide 
• 1346146-04-0 (R)-5-(5-bromo-2-fluorophenyl)-6,6-difluoro-5,7,7-trimethyl-[1,4]oxazepan-3-one 
• 1401241-43-7 (R)-6,6-difluoro-5-(2-fluoro-5-pyrimidin-5-yl-phenyl)-5-methyl-2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine 
• 1401241-84-6 (R)-6,6-difluoro-5-[2-fluoro-5-(2-methyl-thiazol-4-ylethynyl)-phenyl]-5,7,7-trimethyl-[1,4]oxazepan-3-one 

Relevant articles and documents

1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention relates to 1,4-Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pres

1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention relates to 1,4 Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

1,3-OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention provides compounds of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present inv